U.S. markets closed
  • S&P 500

    3,693.23
    -64.76 (-1.72%)
     
  • Dow 30

    29,590.41
    -486.27 (-1.62%)
     
  • Nasdaq

    10,867.93
    -198.88 (-1.80%)
     
  • Russell 2000

    1,679.59
    -42.72 (-2.48%)
     
  • Crude Oil

    79.43
    -4.06 (-4.86%)
     
  • Gold

    1,651.70
    -29.40 (-1.75%)
     
  • Silver

    18.83
    -0.78 (-3.99%)
     
  • EUR/USD

    0.9693
    -0.0145 (-1.47%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • GBP/USD

    1.0857
    -0.0398 (-3.54%)
     
  • USD/JPY

    143.3300
    +0.9950 (+0.70%)
     
  • BTC-USD

    19,114.40
    +430.50 (+2.30%)
     
  • CMC Crypto 200

    434.61
    -9.92 (-2.23%)
     
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • Nikkei 225

    27,153.83
    -159.30 (-0.58%)
     

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates

·8 min read

- Company is advancing its integrin program and on schedule for initiating clinical studies in 2023

- Expanding immuno-oncology pipeline through strategic transactions remains key priority

- Cash and investments on hand of $98.3 million funds operations into the first quarter of 2024

NORWOOD, Mass., March 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for the fourth quarter and year-end of 2021.

Corbus Pharmaceuticals Logo (PRNewsfoto/Corbus Pharmaceuticals Holdings, Inc.)
Corbus Pharmaceuticals Logo (PRNewsfoto/Corbus Pharmaceuticals Holdings, Inc.)

Key Corporate and Program Updates:

  • Hired Rachael Brake, Ph.D., as Chief Scientific Officer, strengthening the Company's capabilities to expand and develop its innovative immuno-oncology pipeline.

  • Anti-integrin monoclonal antibodies (mAbs) program targeting the inhibition of TGFβ is progressing on schedule.

  • The 2nd generation cannabinoid receptor type 1 (CB1) inverse agonist program is progressing through preclinical studies and regulatory pathway evaluation. In animal models of diet-induced obesity, Corbus compounds induce weight loss and impact multiple metabolic parameters, both as monotherapies and in combination with GLP-1 receptor agonists.

  • Topline data from the National Institutes of Health-sponsored Phase 2 study of lenabasum in systemic lupus erythematosus is expected in the first half of 2022. The Company will seek partnerships to fund further development.

"We are executing on our plan to transform Corbus into a company with a novel and diversified pipeline focusing on the nexus between the immune system and cancer. Our integrin program is progressing on schedule and we look forward to entering the clinic in 2023," commented Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "We are actively engaging in business development activities with the goal of expanding our immuno-oncology pipeline."

Financial Results for Fourth Quarter and Year-End December 31, 2021:

Revenue from awards and licenses was $0 for the three months ended December 31, 2021, compared to approximately $658,000 in the comparable period in 2020. For the year ended December 31, 2021, revenue from awards and licenses was $882,000, compared to $3,937,000 in the comparable period in 2020.

Operating expenses decreased by $11.5 million to approximately $10.0 million for the three months ended December 31, 2021, compared to $21.5 million in the comparable period in the prior year. For the year ended December 31, 2021, operating expenses decreased by $69.9 million to approximately $56.9 million, compared to $126.7 million in the comparable period in the prior year. The decrease was primarily attributable to decreased clinical trial and drug manufacturing costs, and an overall reduction in compensation expense.

The Company reported a net loss of approximately $10.3 million, or a net loss per diluted share of $0.08, for the three months ended December 31, 2021, compared to a net loss of approximately $8.6 million, or a net loss per diluted share of $0.10, for the same period in 2020. For the year ended December 31, 2021, the Company reported a net loss of approximately $45.6 million, or a net loss per diluted share of $0.37, compared to a net loss of approximately $111.3 million, or a net loss per diluted share of $1.42 for the same period in 2020.

As of December 31, 2021, the Company has $98.3 million of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based on the current planned expenditures.

About Corbus

Corbus is an immunology company committed to connecting innovation to our purpose of improving lives by developing new medicines that target the nexus between the immune system and cancer. Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
CRBP@jtcir.com
(833) 475-8247

Corbus Pharmaceuticals Holdings, Inc.

Condensed Consolidated Balance Sheets




December 31, 2021



December 31, 2020


ASSETS







Current assets:







Cash and cash equivalents


$

25,006,632



$

85,433,441


Investments



72,640,520





Restricted cash



192,475




350,000


Stock subscriptions receivable






960,033


Prepaid expenses and other current assets



2,365,010




3,712,861


Contract asset






1,618,296


Total current assets



100,204,637




92,074,631


Restricted cash



477,425




669,900


Property and equipment, net



2,392,696




4,067,837


Operating lease right of use assets



4,609,110




5,248,525


Other assets



46,385




234,038


Total assets


$

107,730,253



$

102,294,931


LIABILITIES AND STOCKHOLDERS' EQUITY







Current liabilities:







Notes payable


$

767,938



$

710,158


Accounts payable



1,782,277




7,381,183


Accrued expenses



10,093,312




22,005,432


Derivative liability



133,710




797,000


Operating lease liabilities, current



1,136,948




1,004,063


Current portion of long-term debt



3,093,344





Total current liabilities



17,007,529




31,897,836


Long-term debt, net of debt discount



15,636,275




18,029,005


Other long-term liabilities



22,205





Operating lease liabilities, noncurrent



5,956,217




7,093,165


Total liabilities



38,622,226




57,020,006


Stockholders' equity







Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares
issued and outstanding at December 31, 2021 and 2020







Common stock, $0.0001 par value; 300,000,000 shares authorized,
125,230,881 shares outstanding at December 31, 2021 and 150,000,000
shares authorized, and 98,852,696 shares issued and outstanding at
December 31, 2020



12,523




9,885


Additional paid-in capital



418,891,713




349,358,378


Accumulated deficit



(349,733,764)




(304,093,338)


Accumulated other comprehensive loss



(62,445)





Total stockholders' equity



69,108,027




45,274,925


Total liabilities and stockholders' equity


$

107,730,253



$

102,294,931


Corbus Pharmaceuticals Holdings, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)




For the Three Months Ended
December 31,



For the Years Ended
December 31,




2021



2020



2021



2020


Revenue from awards


$



$

658,204



$

881,705



$

3,937,230


Operating expenses:













Research and development



5,763,601




16,110,287




36,445,285




98,267,213


General and administrative



4,234,760




5,360,231




20,425,444




28,480,250


Total operating expenses



9,998,361




21,470,518




56,870,729




126,747,463


Operating loss



(9,998,361)




(20,812,314)




(55,989,024)




(122,810,233)


Other income (expense), net:













Other income (expense), net



109,664




13,266,206




11,899,992




13,270,211


Interest income (expense), net



(390,899)




(679,704)




(1,830,486)




(1,028,359)


Change in fair value of derivative liability



(6,853)




(40,000)




663,290




(251,000)


Foreign currency exchange gain (loss),
net



25,716




(346,058)




(384,198)




(449,999)


Other income (expense), net



(262,372)




12,200,444




10,348,598




11,540,853


Net loss


$

(10,260,733)



$

(8,611,870)



$

(45,640,426)



$

(111,269,380)


Net loss per share, basic and diluted


$

(0.08)



$

(0.10)



$

(0.37)



$

(1.42)


Weighted average number of common
shares outstanding, basic and diluted



125,230,881




87,207,293




122,990,011




78,133,289


Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-reports-fourth-quarter-and-year-end-2021-financial-results-and-provides-corporate-updates-301497250.html

SOURCE Corbus Pharmaceuticals Holdings, Inc.